Please Wait.....
Report
Middle East and Africa Hemoglobinopathies Market Report and Forecast 2024-2032
Market Report I 2024-06-26 I 140 Pages I EMR Inc.
Middle East and Africa Hemoglobinopathies Market Report and Forecast 2024-2032
Middle East and Africa Hemoglobinopathies Market Size
The global hemoglobinopathies market was valued at USD 6.9 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the rising prevalence of genetic disorders. It is expected to grow at a CAGR of 9.7% during the forecast period of 2024-2032, with the values likely to attain USD 15.9 billion by 2032.
Middle East and Africa Hemoglobinopathies Market Outlook
- Recent data reveals that thalassemia and sickle cell anemia cause a substantial impact on morbidity and mortality. The high prevalence of hemoglobinopathies which can be attributed to the genetic predisposition and high rates of consanguineous marriages in the region is expected to fuel market demand.
- One of the major Middle East and Africa hemoglobinopathies market trends is the surge in regulatory approvals of advanced therapies by health authorities. In January 202 4, the Saudi Food and Drug Authority (SFDA) approved Vertex Pharmaceuticals and CRISPR Therapeutics' Casgevy, a one-time gene-editing therapy leveraging a gene-editing tool called CRISPR/Cas9 to treat sickle cell disease (SCD) in adults and adolescents aged 12 and above.
- The market share is influenced by the increasing awareness campaigns coupled with the rising healthcare expenditures, leading to early diagnosis and better management of these inherited disorders.
Middle East and Africa Hemoglobinopathies Market Analysis
Hemoglobinopathies comprise a group of genetic disorders affecting the structure, function, or production of hemoglobin. The advancements in the global hemoglobinopathies market are increasingly being introduced into the Middle East and African countries. The penetration of such new and innovative treatments in the regional market are positively impacting the standard of care and clinical outcomes for patients with conditions like sickle cell disease and thalassemia. Moreover, the increasing awareness campaigns and advocacy efforts coupled with the rising healthcare expenditure are leading to early diagnosis and better management of these inherited disorders which are poised to significantly contribute to the Middle East and Africa hemoglobinopathies market growth.
The high prevalence of hemoglobinopathies in the region which can be attributed to the genetic predisposition and high rates of consanguineous marriages directly affects the market dynamics. Recent data reveals that thalassemia and sickle cell anemia cause a substantial impact on morbidity and mortality among the affected individuals. Alpha-thalassemia is reported to be prevalent in the Middle Eastern countries. In Saudi Arabia, beta-thalassemia and sickle cell anemia are estimated to be 13.6 and 49.6 per 1000 population, respectively . The growing burden of these hemoglobin disorders is projected to fuel the need for effective diagnostics and treatment solutions to manage such conditions, thereby boosting the Middle East and Africa hemoglobinopathies market demand.
One of the major market trends is the surge in regulatory approvals of novel treatments by the health agencies in the region. In January 202 4, the Saudi Food and Drug Authority (SFDA) approved Casgevy (exagamglogene autotemcel) which is a one-time gene-editing therapy leveraging a gene-editing tool called CRISPR/Cas9 to treat sickle cell disease (SCD) in adults and adolescents aged 12 and above who experience recurrent vaso-occlusive crises. Developed jointly by biotechnology companies Vertex Pharmaceuticals and CRISPR Therapeutics, this gene editing therapy represents the first medicine to receive and be approved via the SFDA Breakthrough Designation pathway. The presence of such regulatory reforms that accelerate the review of therapies that address unmet medical needs is likely to elevate the market value.
Middle East and Africa Hemoglobinopathies Market Segmentation??
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Thalassemia
Sickle Cell Disease
Other Hb Variants Diseases
Market Breakup by Treatment
Stem-Cell Transplantation
Blood Transfusions
Analgesics
Antibiotics
Ace Inhibitors
Hydroxyurea
Monoclonal Antibody Medication
Others
Market Breakup by Test Type
Routine Red Blood Cell (RBC) Count
Genetic Testing
Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
Hemoglobin Isoelectric Focusing (Hb IEF)
Hemoglobin electrophoresis (Hb ELP)
Hemoglobin Solubility Test
Market Breakup by End User
Hospitals and Clinics
Diagnostics Laboratories
Others
Market Breakup by Country
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Leading Players in the Middle East and Africa Hemoglobinopathies Market
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Bio-Rad Laboratories, Inc.
- Bristol-Myers Squibb Company
- Novartis AG
- Pfizer Limited
- Merck KGaA
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Neusoft Corporation
- Emmaus
- Biogen
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
FAQs
- What is the Middle East and Africa hemoglobinopathies market forecast outlook for 2024-2032?
The Middle East and Africa hemoglobinopathies market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 9.7% during the forecast period of 2024-2032 and is likely to reach a market value of USD 15.9 billion by 2032.
- What are the major factors aiding the Middle East and Africa hemoglobinopathies market demand?
The rising prevalence of thalassemia and sickle cell anemia is fuelling the demand for the market.
- What are the major Middle East and Africa hemoglobinopathies market trends?
One of the significant trends in the market is the surge in regulatory approvals of advanced therapies by health authorities. In January 2024, the Saudi Food and Drug Authority (SFDA) approved Casgevy, a one-time gene-editing therapy to treat sickle cell disease (SCD) in adults and adolescents aged 12 and above.
- What is the market segmentation based on the type?
Based on the type, the market is segmented into thalassemia, sickle cell disease, and other Hb variant diseases.
- What are the various treatments available in the market?
Treatments available in the market include stem-cell transplantation, blood transfusions, analgesics, antibiotics, ace inhibitors, hydroxyurea, and monoclonal antibody medication, among others.
- What is the market breakup by test type?
By test type, the market is divided into routine red blood cell (RBC) count, genetic testing, hemoglobin by high performance liquid chromatograph (Hb HPLC), hemoglobin isoelectric focusing (Hb IEF), hemoglobin electrophoresis (Hb ELP), and hemoglobin solubility test.
- What are the major end users of the market?
End users of the market are hospitals, clinics, and diagnostics laboratories, among others.
- What is the market segmentation by countries?
The market segmentation by countries includes Saudi Arabia, the United Arab Emirates, Nigeria, and South Africa, among others.
- Who are the key players involved in the Middle East and Africa hemoglobinopathies market?
The key players in the market are Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Novartis AG, Pfizer Limited, Merck KGaA, Alnylam Pharmaceuticals, Inc., Sanofi, Neusoft Corporation, Emmaus, and Biogen.
Meta description
The Middle East and Africa hemoglobinopathies market is poised for growth, driven by the expansion of the global market, which was valued at USD 6.9 billion in 2023 and is projected to grow at a CAGR of 9.7% during the forecast period of 2024-2032.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Middle East and Africa Hemoglobinopathies Market Overview
3.1 Middle East and Africa Hemoglobinopathies Market Historical Value (2017-2023)
3.2 Middle East and Africa Hemoglobinopathies Market Forecast Value (2024-2032)
4 Middle East and Africa Hemoglobinopathies Market Landscape*
4.1 Middle East and Africa Hemoglobinopathies: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Middle East and Africa Hemoglobinopathies: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Treatment
5 Middle East and Africa Hemoglobinopathies Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter's Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Middle East and Africa Hemoglobinopathies Market Segmentation (2017-2032)
6.1 Middle East and Africa Hemoglobinopathies Market (2017-2032) by Type
6.1.1 Market Overview
6.1.2 Thalassemia
6.1.3 Sickle Cell Disease
6.1.4 Other Hb Variants Diseases
6.2 Middle East and Africa Hemoglobinopathies Market (2017-2032) by Treatment
6.2.1 Market Overview
6.2.2 Stem-Cell Transplantation
6.2.3 Blood Transfusions
6.2.4 Analgesics
6.2.5 Antibiotics
6.2.6 Ace Inhibitors
6.2.7 Hydroxyurea
6.2.8 Monoclonal Antibody Medication
6.2.9 Others
6.3 Middle East and Africa Hemoglobinopathies Market (2017-2032) by Test Type
6.3.1 Market Overview
6.3.2 Routine Red Blood Cell (RBC) Count
6.3.3 Genetic Testing
6.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
6.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
6.3.6 Hemoglobin Electrophoresis (Hb ELP)
6.3.7 Hemoglobin Solubility Test
6.4 Middle East and Africa Hemoglobinopathies Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Diagnostics Laboratories
6.4.4 Others
6.5 Middle East and Africa Hemoglobinopathies Market (2017-2032) by Country
6.5.1 Market Overview
6.5.2 Saudi Arabia
6.5.3 United Arab Emirates
6.5.4 Nigeria
6.5.5 South Africa
6.5.6 Others
7 Saudi Arabia Hemoglobinopathies Market (2017-2032)
7.1 Saudi Arabia Hemoglobinopathies Market (2017-2032) by Type
7.1.1 Market Overview
7.1.2 Thalassemia
7.1.3 Sickle Cell Disease
7.1.4 Other Hb Variants Diseases
7.2 Saudi Arabia Hemoglobinopathies Market (2017-2032) by Treatment
7.2.1 Market Overview
7.2.2 Stem-Cell Transplantation
7.2.3 Blood Transfusions
7.2.4 Analgesics
7.2.5 Antibiotics
7.2.6 Ace Inhibitors
7.2.7 Hydroxyurea
7.2.8 Monoclonal Antibody Medication
7.2.9 Others
7.3 Saudi Arabia Hemoglobinopathies Market (2017-2032) by Test Type
7.3.1 Market Overview
7.3.2 Routine Red Blood Cell (RBC) Count
7.3.3 Genetic Testing
7.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
7.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
7.3.6 Hemoglobin Electrophoresis (Hb ELP)
7.3.7 Hemoglobin Solubility Test
7.4 Saudi Arabia Hemoglobinopathies Market (2017-2032) by End User
7.4.1 Market Overview
7.4.2 Hospitals and Clinics
7.4.3 Diagnostics Laboratories
7.4.4 Others
8 United Arab Emirates Hemoglobinopathies Market (2017-2032)
8.1 United Arab Emirates Hemoglobinopathies Market (2017-2032) by Type
8.1.1 Market Overview
8.1.2 Thalassemia
8.1.3 Sickle Cell Disease
8.1.4 Other Hb Variants Diseases
8.2 United Arab Emirates Hemoglobinopathies Market (2017-2032) by Treatment
8.2.1 Market Overview
8.2.2 Stem-Cell Transplantation
8.2.3 Blood Transfusions
8.2.4 Analgesics
8.2.5 Antibiotics
8.2.6 Ace Inhibitors
8.2.7 Hydroxyurea
8.2.8 Monoclonal Antibody Medication
8.2.9 Others
8.3 United Arab Emirates Hemoglobinopathies Market (2017-2032) by Test Type
8.3.1 Market Overview
8.3.2 Routine Red Blood Cell (RBC) Count
8.3.3 Genetic Testing
8.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
8.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
8.3.6 Hemoglobin electrophoresis (Hb ELP)
8.3.7 Hemoglobin Solubility Test
8.4 United Arab Emirates Hemoglobinopathies Market (2017-2032) by End User
8.4.1 Market Overview
8.4.2 Hospitals and Clinics
8.4.3 Diagnostics Laboratories
8.4.4 Others
9 Nigeria Hemoglobinopathies Market (2017-2032)
9.1 Nigeria Hemoglobinopathies Market (2017-2032) by Type
9.1.1 Market Overview
9.1.2 Thalassemia
9.1.3 Sickle Cell Disease
9.1.4 Other Hb Variants Diseases
9.2 Nigeria Hemoglobinopathies Market (2017-2032) by Treatment
9.2.1 Market Overview
9.2.2 Stem-Cell Transplantation
9.2.3 Blood Transfusions
9.2.4 Analgesics
9.2.5 Antibiotics
9.2.6 Ace Inhibitors
9.2.7 Hydroxyurea
9.2.8 Monoclonal Antibody Medication
9.2.9 Others
9.3 Nigeria Hemoglobinopathies Market (2017-2032) by Test Type
9.3.1 Market Overview
9.3.2 Routine Red Blood Cell (RBC) Count
9.3.3 Genetic Testing
9.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
9.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
9.3.6 Hemoglobin electrophoresis (Hb ELP)
9.3.7 Hemoglobin Solubility Test
9.4 Nigeria Hemoglobinopathies Market (2017-2032) by End User
9.4.1 Market Overview
9.4.2 Hospitals and Clinics
9.4.3 Diagnostics Laboratories
9.4.4 Others
10 South Africa Hemoglobinopathies Market (2017-2032)
10.1 South Africa Hemoglobinopathies Market (2017-2032) by Type
10.1.1 Market Overview
10.1.2 Thalassemia
10.1.3 Sickle Cell Disease
10.1.4 Other Hb Variants Diseases
10.2 South Africa Hemoglobinopathies Market (2017-2032) by Treatment
10.2.1 Market Overview
10.2.2 Stem-Cell Transplantation
10.2.3 Blood Transfusions
10.2.4 Analgesics
10.2.5 Antibiotics
10.2.6 Ace Inhibitors
10.2.7 Hydroxyurea
10.2.8 Monoclonal Antibody Medication
10.2.9 Others
10.3 South Africa Hemoglobinopathies Market (2017-2032) by Test Type
10.3.1 Market Overview
10.3.2 Routine Red Blood Cell (RBC) Count
10.3.3 Genetic Testing
10.3.4 Hemoglobin by High Performance Liquid Chromatograph (Hb HPLC)
10.3.5 Hemoglobin Isoelectric Focusing (Hb IEF)
10.3.6 Hemoglobin electrophoresis (Hb ELP)
10.3.7 Hemoglobin Solubility Test
10.4 South Africa Hemoglobinopathies Market (2017-2032) by End User
10.4.1 Market Overview
10.4.2 Hospitals and Clinics
10.4.3 Diagnostics Laboratories
10.4.4 Others
12. Regulatory Framework
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Market Share by Top 5 Companies
17.2 Bio-Rad Laboratories, Inc.
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bristol-Myers Squibb Company
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Novartis AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Pfizer Limited
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Merck KGaA
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Alnylam Pharmaceuticals, Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Sanofi
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Neusoft Corporation
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Emmaus
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Biogen
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
18 Middle East and Africa Hemoglobinopathies Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security